IraqiMPerdomoJYanFChoiPY-ImChongBH.Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica2015;
100: 623–632.
2.
ZhuF-XHuangJ-YYeZWenQ-QCheng-Chung WeiJ.Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis2020; 79: 793–799.
3.
HarleyJBKellyJAKaufmanKM.Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immun2006;
28: 119–130.
4.
İnançMArtim-EsenBDiz-KüçükkayaR. High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern. Ann Rheum Dis2020. DOI:10.1136/annrheumdis-2020-21834.
5.
HughesGR.The antiphospholipid syndrome: ten years on. Lancet1993;
342: 341–344.
6.
GoulielmosGNZervouMI.Risk of systemic lupus erythematosus inpatients with idiopathic thrombocytopenic purpura: population-based cohort study. Ann Rheum Dis2020; Epub ahead of print 22 July 2020. DOI: 10.1136/annrheumdis-2020-21812.
7.
Ortiz-FernándezLSawalhaAH.Genetics of antiphospholipid syndrome. Curr Rheumatol Rep2019;
21: 65.
8.
Sugiura-OgasawaraMOmaeYKawashimaM, et al.
The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet2017;
62: 831–838.
9.
BergmannAKGraceRFNeufeldEJ.Genetic studies in pediatric ITP: outlook, feasibility, and requirements. Ann Hematol2010;
89: 95–S103.
10.
KarassaFBBijMDaviesKA, et al.
Role of the Fcγ receptor IIA polymorphism in the antiphospholipid syndrome. Arthr Rheum2003;
48: 1930–1938.
